03681 SINOMAB BIO-B
- 1.850
- +0.020+1.09%
SINOMAB BIO-B News
Agency: The synthetic biology sector showed a high increase in Q1 performance, and policy expectations accelerated valuation repair
Currently, the core competitiveness of biological manufacturing companies lies in product development and implementation capabilities. They are optimistic about targets with successful cases, leading positions, high-quality product reserves, and a boom in downstream demand.
Baili Tianheng and Shenzhou Cell turned losses into profits! Many biomedical companies on the Science and Technology Innovation Board ushered in a “good start” in Q1
In the first quarter of 2024, many parts of the country successively issued relevant policies to support the high-quality development of the biomedical industry or innovative pharmaceutical devices to continuously optimize the biomedical innovation environment.
中國抗體-B：年度報告2023
China Antibody-B (03681) released annual results, achieving revenue of 1.3665 million yuan, and all businesses achieved expected performance
China Antibody-B (03681) announced its annual results for the year ended December 31, 2023, and the group achieved revenue...
SINOMAB BIO-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023; CHANGE IN USE OF PROCEEDS; PROPOSED AMENDMENT TO THE 2022 SHARE OPTION SCHEME; AND PROPOSED REFRESHMENT OF SCHEME MANDATE LIMIT AND SERVICE PROVIDER SUBLIMIT
A major favorable raid, and the 1.6 trillion innovative drug sector is booming!
The advantage suddenly “smashed” into the pharmaceutical sector!
China Antibody-B (03681.HK) plans to hold a board meeting on March 25 to consider and approve annual results
Gelonghui March 12 | China Antibody-B (03681.HK) announced that a board meeting will be held on March 25, 2024 (Monday) to consider and approve the Group's annual results and announcements for the year ended December 31, 2023, and to deal with other matters.
SINOMAB BIO-B: DATE OF BOARD MEETING
A quick overview of the Hong Kong market | The Hang Seng Index rose nearly 2%, and the Science Index rose nearly 3%; insurance, real estate and other sectors were strong throughout the day
Technet stocks were strong. Meituan rose nearly 5%, Bilibili and Kuaishou rose more than 3%, Xiaomi and Jingdong rose more than 2%, Baidu, Ali, and Tencent rose more than 1%, and NetEase followed; insurance stocks were strong throughout the day. China Ping An rose more than 6%, China Life Insurance rose nearly 5%, and AIA Insurance rose more than 2%.
China Antibody-B (03681): Wang Shanchun appointed as Executive Director
China Antibody-B (03681) announced that Wang Shanchun has been appointed as the company's executive director since February 2024...
Intraday Overview | The three major indices rose slightly, and the Tech Index rose nearly 2%; auto stocks and biotech stocks rose strongly. NIO rose nearly 8%, and Pharmaceutical Biotech rose more than 9%
Most Technology Network stocks rose, with Station B up more than 4%; Meituan and NetEase up more than 3%; mobile phone equipment stocks showed active performance, with Shunyu Optical Technology up more than 7% and Gaowei Electronics by more than 5%; pharmaceutical distribution stocks improved, Ali Health rose more than 8%, and JD Health rose nearly 5%.
Intraday Overview | The Tech Index fell more than 2%, Apple concept stocks and pharmaceutical stocks had the highest declines, and Shunyu Optical Technology fell more than 8%
Technet stocks collectively weakened, with Xiaomi falling nearly 4%, Meituan falling nearly 3%, and Kuaishou falling more than 2%; domestic housing stocks continued to decline, with Country Garden falling more than 3%; Longhu Group, Xincheng Development, and Sunac China falling nearly 2%; auto stocks were weak, with Zero Sports Auto and NIO falling more than 5%, and Xiaopeng Motors falling more than 4%.
SinoMab BioScience Raises HK$62.2 Million From Thirteen Share Subscriptions
SinoMab BioScience (HKG:3681) raised net proceeds worth HK$62.2 million from the completion of thirteen share subscriptions. An aggregate of 48,322,093 shares were issued to subscribers for HK$1.29 ap
China Antibody-B (03681) completed the issuance of 48.321 million subscribed shares
China Antibody-B (03681) issued an announcement. Since the prerequisites contained in the 13 subscription agreements have been met, according to...
Hong Kong Stock Concept Tracker | Important! A new drug for Alzheimer's disease has been approved in China, and the drug development and diagnosis industry chain is worth paying attention to (with concept stocks)
The Guojin Securities Research Report pointed out that there are many pharmaceutical companies participating in AD research and development in China, and there are pharmaceutical companies worthy of attention in terms of biopharmaceuticals and chemicals.
SinoMab BioScience Issues 56.8 Million Shares to 15 Investors
SinoMab BioScience (HKG:3681) issued 56,834,719 shares to 15 investors at HK$1.29 apiece for a total of HK$73.3 million, a Thursday filing said. The net subscription price is seen to be at HK$73.2 mil
Selected Announcements | China Evergrande Plans to Sell Shanghai's North Bund Project for 663 Million Yuan; Hanson Pharmaceuticals' Three Innovative Drugs Are Included in the New National Health Insurance Catalogue
China Eastern Airlines Co., Ltd. plans to increase the capital of Sichuan Airlines Co., Ltd. by 1.2 billion yuan; Minimally Invasive Medicine: Heart Health Technology plans to allocate a total of 107.481 million new A shares, with a net raise of 1,809 million yuan; China Antibody plans to discount about 18.35% to issue 56.83447 million shares, with a net raise of HK$73.182 million.
SinoMab Doses First Batch of Subjects in Phase 1 Trial of Atopic Dermatitis Drug in China
SinoMab BioScience (HKG:3681) dosed the first batch of subjects in the Phase 1 trial of its SM17 drug in China, according to a Monday filing. The trial intends to determine the safety, pharmacokinetic
Selected Announcements | Sunac China: Hangzhou Xiao agreed to transfer 15.625% of Zhejiang Qilong's shares and bonds
Bosideng: Profit attributable to shareholders for the interim period in 2023 was 919 million yuan, up 25.1% year on year; China Education Holdings: Annual adjusted net profit increased 6.0% to 1,908 billion yuan.
Innovative drugs, the standard-bearer of the Hong Kong stock market
However, the protagonist leading the rebound of A/H shares in this round is innovative pharmaceuticals+consumer electronics. Judging from the past half month, consumer electronics has performed better in A-shares, while innovative drugs have performed more fiercely in Hong Kong stocks.
Analysis
Price Target
No Data
